Dr. Thomas Andreas Prohaska, MD

Dr. Prohaska practices at UCSD Hillcrest Medical Center in San Diego, California.

Dr. Prohaska's NPI, 1861889644, was assigned on April 20, 2015. Dr. Prohaska graduated from University of Vienna Faculty of Medicine in 2013. Dr. Prohaska holds California license A150882.

Dr. Prohaska's primary practice is UCSD Hillcrest Medical Center, at 200 W Arbor Dr, San Diego, CA 92103 in San Diego County. The practice phone is (619) 543-6222.

Dr. Prohaska's primary practice is UCSD Hillcrest Medical Center in San Diego, California. Dr. Prohaska is also affiliated with Hillcrest Medical Center. The medical group on file is UC San Diego Health.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Prohaska practices. Vendor and product names are available with a free account.

Cardiovascular disease is Dr. Prohaska's primary specialty in the NPI Registry, under taxonomy code 207RC0000X. Dr. Prohaska is board certified in cardiovascular disease by the American Board of Internal Medicine. Dr. Prohaska is licensed in California.

Dmand AI lists atrial fibrillation and flutter, chronic hypertension, coronary artery disease, heart failure and high cholesterol among the conditions Dr. Prohaska treats.

CMS data shows 113 Medicare services from Dr. Prohaska across 4 procedure codes in 2024, for 82 Medicare patients. Medicare paid $7,599 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 82 Medicare patients who saw Dr. Prohaska in 2024. The largest group is 65 to 74, with 36 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 46% are also on Medicaid. Their average risk score is 2.01, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Prohaska's median patient age at 69, with 44% women.

In 2024, Dr. Prohaska wrote 115 Medicare Part D claims for 41 patients. 91% of them were for generic drugs. CMS names the drug for 67 of them, across 4 drugs with 11 or more claims each, at $835 in total drug cost. In 2023, CMS named 27 claims across 2 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 91 out of 100 for Dr. Prohaska for performance year 2024, reported as part of a group. Dr. Prohaska accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 16 papers to Dr. Prohaska, published from 2012 to 2025. 2018 was the busiest year, with 2. The most frequent topics are Hypertriglyceridemia, Oligonucleotides and Triglycerides. Dr. Prohaska has published most often in N Engl J Med. Dr. Prohaska's most frequent co-authors are Sotirios Tsimikas, MD, Joseph L. Witztum, MD and Veronica Alexander, MD.

CMS Open Payments shows 3 general payments to Dr. Prohaska from 3 drug and device companies in 2018. Food and beverage make up the largest share, 100% of the total. Regeneron Pharmaceuticals, Inc. paid the most, $128.

Dr. Prohaska graduated from University of Vienna Faculty of Medicine in 2013.

Dr. Prohaska is in network with 14 carriers, including Aetna, Blue Cross Blue Shield of Michigan and United Healthcare. PPO plans come from the most carriers, 9. Check the plan with the practice before a visit.